Patient-derived tumor xenografts (PDXs), in which tumor fragments surgically dissected from
cancer patients are directly transplanted into immunodeficient mice, have emerged as a …

Metastatic melanoma is challenging to manage. Although targeted-and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …

The excessive lactate in the tumor microenvironment always leads to poor therapeutic
outcomes of chemotherapy. In this study, a self-driven bioreactor (defined as SO@ MDH …

Cancer-specific DNA repair defects are abundant in malignant tissue and present an
opportunity to capitalize on these aberrations for therapeutic benefit. Early preclinical data …

Patient‐derived xenograft (PDX) models are widely used as preclinical cancer models and
are considered better than cell culture models in recapitulating the histological features …

Patient-derived xenograft (PDX) models are used as powerful tools for understanding
cancer biology in PDX clinical trials and co-clinical trials. In this systematic review, we focus …

Chimeric antigen receptors (CAR) can transmit signals akin to those from activated T-cell
receptors when bound to a cell surface target. CAR-expressing T cells against CD19 can …

Purpose: Unlike advances in the genomics-driven precision treatment of cutaneous
melanomas, the current poor understanding of the molecular basis of mucosal melanomas …

Purpose: Neratinib is an irreversible, pan-HER tyrosine kinase inhibitor that is FDA
approved for HER2-overexpressing/amplified (HER2+) breast cancer. In this preclinical …

Immunotherapy is at the forefront of cancer treatment. The advent of numerous novel
approaches to cancer immunotherapy, including immune checkpoint antibodies, adoptive …